Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative
This study longitudinally examined participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants incl...
Gespeichert in:
| Veröffentlicht in: | Neurobiology of aging 2023-07, Vol.127, p.33-42 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | |
| container_start_page | 33 |
| container_title | Neurobiology of aging |
| container_volume | 127 |
| creator | Groechel, Renée C. Tripodis, Yorghos Alosco, Michael L. Mez, Jesse Qiu, Wei Qiao Mercier, Gustavo Goldstein, Lee Budson, Andrew E. Kowall, Neil W. Killiany, Ronald J. |
| description | This study longitudinally examined participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. Of these participants, 68 showed amyloid conversion as measured on florbetapir PET, and the other 68 did not. Amyloid converters and non-converters were chosen to have representative demographic data (age, education, sex, diagnostic status, and race). The amyloid converter group showed increased prevalence of APOE ε4 (p |
| doi_str_mv | 10.1016/j.neurobiolaging.2023.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2800627220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197458023000519</els_id><sourcerecordid>2800627220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-1d5fcdc8724796d430530d276bf43650e8a9b9ee22b7438a457ddd79e397ac713</originalsourceid><addsrcrecordid>eNqNkcFq3DAQhkVoabbbvkLQoYdevB1JtmVDLyE0bSGQS3sWsjR2tNiSK9kp6fv0PavdTQK9BQYJhu-ff4afkA8MdgxY_Wm_87jG0Lkw6sH5YceBix3kguqMbFhVNQUrW_mKbIC1siirBs7J25T2ACBLWb8h50JCKZqGbcjfS-9XPbo_aKm5037ARJ2nUS9IQ0_19DAGZ6nFOSS3uOCp9pYeN7A4oMdMHrsR6RAxy-JBP-u4OONm7ZdEf98F2qEJEz7PO027R7pkz_yEhEcs4qSz_AnzOOgD9o687vWY8P3jvyU_r7_8uPpW3Nx-_X51eVMY0bClYLbqjTWN5KVsa1sKqARYLuuuL0VdATa67VpEzjuZ79dlJa21skXRSm0kE1vy8TR3juHXimlRk0sGx1F7DGtSvAGoueQcMvr5hJoYUorYqzm6SccHxUAdglJ79X9Q6hCUglx5rS25eHRauwnts_gpmQxcnwDM9947jCoZh96gdRHNomxwL3P6B-FPsdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2800627220</pqid></control><display><type>article</type><title>Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Groechel, Renée C. ; Tripodis, Yorghos ; Alosco, Michael L. ; Mez, Jesse ; Qiu, Wei Qiao ; Mercier, Gustavo ; Goldstein, Lee ; Budson, Andrew E. ; Kowall, Neil W. ; Killiany, Ronald J.</creator><creatorcontrib>Groechel, Renée C. ; Tripodis, Yorghos ; Alosco, Michael L. ; Mez, Jesse ; Qiu, Wei Qiao ; Mercier, Gustavo ; Goldstein, Lee ; Budson, Andrew E. ; Kowall, Neil W. ; Killiany, Ronald J. ; for the Alzheimer’s Disease Neuroimaging Initiative ; Alzheimer’s Disease Neuroimaging Initiative</creatorcontrib><description>This study longitudinally examined participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. Of these participants, 68 showed amyloid conversion as measured on florbetapir PET, and the other 68 did not. Amyloid converters and non-converters were chosen to have representative demographic data (age, education, sex, diagnostic status, and race). The amyloid converter group showed increased prevalence of APOE ε4 (p < 0.001), greater annualized percent volume loss in selected magnetic resonance imaging (MRI) regions (p < 0.05), lower cerebrospinal fluid Aβ1–42 (p < 0.001), and greater amyloid retention (as measured by standard uptake value ratios) on florbetapir PET scans (p < 0.001) in comparison to the non-converter group. These results provide compelling evidence that important neuropathological changes are occurring alongside amyloid conversion.</description><identifier>ISSN: 0197-4580</identifier><identifier>EISSN: 1558-1497</identifier><identifier>DOI: 10.1016/j.neurobiolaging.2023.03.005</identifier><identifier>PMID: 37043881</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alzheimer Disease - pathology ; Alzheimer’s disease ; Amyloid ; Amyloid beta-Peptides - metabolism ; Aniline Compounds ; Brain - metabolism ; Cognition ; Cognitive Dysfunction - pathology ; Dementia ; Ethylene Glycols ; Humans ; Magnetic resonance imaging ; Positron emission tomography ; Positron-Emission Tomography - methods</subject><ispartof>Neurobiology of aging, 2023-07, Vol.127, p.33-42</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c381t-1d5fcdc8724796d430530d276bf43650e8a9b9ee22b7438a457ddd79e397ac713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neurobiolaging.2023.03.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37043881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Groechel, Renée C.</creatorcontrib><creatorcontrib>Tripodis, Yorghos</creatorcontrib><creatorcontrib>Alosco, Michael L.</creatorcontrib><creatorcontrib>Mez, Jesse</creatorcontrib><creatorcontrib>Qiu, Wei Qiao</creatorcontrib><creatorcontrib>Mercier, Gustavo</creatorcontrib><creatorcontrib>Goldstein, Lee</creatorcontrib><creatorcontrib>Budson, Andrew E.</creatorcontrib><creatorcontrib>Kowall, Neil W.</creatorcontrib><creatorcontrib>Killiany, Ronald J.</creatorcontrib><creatorcontrib>for the Alzheimer’s Disease Neuroimaging Initiative</creatorcontrib><creatorcontrib>Alzheimer’s Disease Neuroimaging Initiative</creatorcontrib><title>Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative</title><title>Neurobiology of aging</title><addtitle>Neurobiol Aging</addtitle><description>This study longitudinally examined participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. Of these participants, 68 showed amyloid conversion as measured on florbetapir PET, and the other 68 did not. Amyloid converters and non-converters were chosen to have representative demographic data (age, education, sex, diagnostic status, and race). The amyloid converter group showed increased prevalence of APOE ε4 (p < 0.001), greater annualized percent volume loss in selected magnetic resonance imaging (MRI) regions (p < 0.05), lower cerebrospinal fluid Aβ1–42 (p < 0.001), and greater amyloid retention (as measured by standard uptake value ratios) on florbetapir PET scans (p < 0.001) in comparison to the non-converter group. These results provide compelling evidence that important neuropathological changes are occurring alongside amyloid conversion.</description><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer’s disease</subject><subject>Amyloid</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Aniline Compounds</subject><subject>Brain - metabolism</subject><subject>Cognition</subject><subject>Cognitive Dysfunction - pathology</subject><subject>Dementia</subject><subject>Ethylene Glycols</subject><subject>Humans</subject><subject>Magnetic resonance imaging</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><issn>0197-4580</issn><issn>1558-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFq3DAQhkVoabbbvkLQoYdevB1JtmVDLyE0bSGQS3sWsjR2tNiSK9kp6fv0PavdTQK9BQYJhu-ff4afkA8MdgxY_Wm_87jG0Lkw6sH5YceBix3kguqMbFhVNQUrW_mKbIC1siirBs7J25T2ACBLWb8h50JCKZqGbcjfS-9XPbo_aKm5037ARJ2nUS9IQ0_19DAGZ6nFOSS3uOCp9pYeN7A4oMdMHrsR6RAxy-JBP-u4OONm7ZdEf98F2qEJEz7PO027R7pkz_yEhEcs4qSz_AnzOOgD9o687vWY8P3jvyU_r7_8uPpW3Nx-_X51eVMY0bClYLbqjTWN5KVsa1sKqARYLuuuL0VdATa67VpEzjuZ79dlJa21skXRSm0kE1vy8TR3juHXimlRk0sGx1F7DGtSvAGoueQcMvr5hJoYUorYqzm6SccHxUAdglJ79X9Q6hCUglx5rS25eHRauwnts_gpmQxcnwDM9947jCoZh96gdRHNomxwL3P6B-FPsdA</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Groechel, Renée C.</creator><creator>Tripodis, Yorghos</creator><creator>Alosco, Michael L.</creator><creator>Mez, Jesse</creator><creator>Qiu, Wei Qiao</creator><creator>Mercier, Gustavo</creator><creator>Goldstein, Lee</creator><creator>Budson, Andrew E.</creator><creator>Kowall, Neil W.</creator><creator>Killiany, Ronald J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202307</creationdate><title>Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative</title><author>Groechel, Renée C. ; Tripodis, Yorghos ; Alosco, Michael L. ; Mez, Jesse ; Qiu, Wei Qiao ; Mercier, Gustavo ; Goldstein, Lee ; Budson, Andrew E. ; Kowall, Neil W. ; Killiany, Ronald J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-1d5fcdc8724796d430530d276bf43650e8a9b9ee22b7438a457ddd79e397ac713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer’s disease</topic><topic>Amyloid</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Aniline Compounds</topic><topic>Brain - metabolism</topic><topic>Cognition</topic><topic>Cognitive Dysfunction - pathology</topic><topic>Dementia</topic><topic>Ethylene Glycols</topic><topic>Humans</topic><topic>Magnetic resonance imaging</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groechel, Renée C.</creatorcontrib><creatorcontrib>Tripodis, Yorghos</creatorcontrib><creatorcontrib>Alosco, Michael L.</creatorcontrib><creatorcontrib>Mez, Jesse</creatorcontrib><creatorcontrib>Qiu, Wei Qiao</creatorcontrib><creatorcontrib>Mercier, Gustavo</creatorcontrib><creatorcontrib>Goldstein, Lee</creatorcontrib><creatorcontrib>Budson, Andrew E.</creatorcontrib><creatorcontrib>Kowall, Neil W.</creatorcontrib><creatorcontrib>Killiany, Ronald J.</creatorcontrib><creatorcontrib>for the Alzheimer’s Disease Neuroimaging Initiative</creatorcontrib><creatorcontrib>Alzheimer’s Disease Neuroimaging Initiative</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurobiology of aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groechel, Renée C.</au><au>Tripodis, Yorghos</au><au>Alosco, Michael L.</au><au>Mez, Jesse</au><au>Qiu, Wei Qiao</au><au>Mercier, Gustavo</au><au>Goldstein, Lee</au><au>Budson, Andrew E.</au><au>Kowall, Neil W.</au><au>Killiany, Ronald J.</au><aucorp>for the Alzheimer’s Disease Neuroimaging Initiative</aucorp><aucorp>Alzheimer’s Disease Neuroimaging Initiative</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative</atitle><jtitle>Neurobiology of aging</jtitle><addtitle>Neurobiol Aging</addtitle><date>2023-07</date><risdate>2023</risdate><volume>127</volume><spage>33</spage><epage>42</epage><pages>33-42</pages><issn>0197-4580</issn><eissn>1558-1497</eissn><abstract>This study longitudinally examined participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. Of these participants, 68 showed amyloid conversion as measured on florbetapir PET, and the other 68 did not. Amyloid converters and non-converters were chosen to have representative demographic data (age, education, sex, diagnostic status, and race). The amyloid converter group showed increased prevalence of APOE ε4 (p < 0.001), greater annualized percent volume loss in selected magnetic resonance imaging (MRI) regions (p < 0.05), lower cerebrospinal fluid Aβ1–42 (p < 0.001), and greater amyloid retention (as measured by standard uptake value ratios) on florbetapir PET scans (p < 0.001) in comparison to the non-converter group. These results provide compelling evidence that important neuropathological changes are occurring alongside amyloid conversion.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37043881</pmid><doi>10.1016/j.neurobiolaging.2023.03.005</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0197-4580 |
| ispartof | Neurobiology of aging, 2023-07, Vol.127, p.33-42 |
| issn | 0197-4580 1558-1497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2800627220 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Alzheimer Disease - pathology Alzheimer’s disease Amyloid Amyloid beta-Peptides - metabolism Aniline Compounds Brain - metabolism Cognition Cognitive Dysfunction - pathology Dementia Ethylene Glycols Humans Magnetic resonance imaging Positron emission tomography Positron-Emission Tomography - methods |
| title | Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T04%3A54%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Annualized%20changes%20in%20rate%20of%20amyloid%20deposition%20and%20neurodegeneration%20are%20greater%20in%20participants%20who%20become%20amyloid%20positive%20than%20those%20who%20remain%20amyloid%20negative&rft.jtitle=Neurobiology%20of%20aging&rft.au=Groechel,%20Ren%C3%A9e%20C.&rft.aucorp=for%20the%20Alzheimer%E2%80%99s%20Disease%20Neuroimaging%20Initiative&rft.date=2023-07&rft.volume=127&rft.spage=33&rft.epage=42&rft.pages=33-42&rft.issn=0197-4580&rft.eissn=1558-1497&rft_id=info:doi/10.1016/j.neurobiolaging.2023.03.005&rft_dat=%3Cproquest_cross%3E2800627220%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2800627220&rft_id=info:pmid/37043881&rft_els_id=S0197458023000519&rfr_iscdi=true |